Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docosahexaenoic acid + lutein
- Development stage
- Preclinical
- Lead developer
- Théa Pharmaceuticals
- Administration
- Oral
01
Overview
A nutritional supplement combination of docosahexaenoic acid (DHA), an omega-3 fatty acid found in the retina, and lutein, a carotenoid that forms part of the macular pigment. This combination has been studied for its effects on increasing macular pigment optical density (MPOD) and potentially preventing age-related macular degeneration (AMD). The compounds appear to work synergistically, with lutein supplementation increasing MPOD eccentrically while DHA results in central increases in MPOD.
- Other names
- lutein + docosahexaenoic acidlutein + DHADHA + lutein
Beyond the preview
Go deeper on docosahexaenoic acid + lutein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docosahexaenoic acid + lutein.